

Pharmacologic Agents for Treatment of Hepatitis C

SCAN Formulary Drugs

Medication	Dosing & Administration	2024 Formulary Status		2025 Formulary Status		Adverse Drug Reactions
		Tier	UM	Tier	UM	
Combination Direct-Acting Antivirals						
EPCLUSA	sofosbuvir/velpatasvir (400 mg/100mg) PO daily	5	[PA]	5	[PA]	Nausea, Headache, fatigue, bradyarrhythmia
HARVONI	ledipasvir/sofosbuvir (90mg/400mg) PO daily	5	[PA]	5	[PA]	Bradycardia if used with amiodarone, fatigue, headache
LEDIPASVIR/ SOFOSBUVIR 90mg-400mg	ledipasvir/sofosbuvir (90mg/400mg) PO daily	5	[PA]	5	[PA]	Bradycardia if used with amiodarone, fatigue, headache
<i>ribavirin</i>	400mg to 600mg PO BID	3		3		Fatigue/asthenia, pyrexia, myalgia Boxed warning: hemolytic anemia may result in worsening of cardiac disease & myocardial infarctions
SOFOSBUVIR/ VELPATASVIR 400mg-100mg	sofosbuvir/velpatasvir (400 mg/100mg) PO daily	5	[PA]	5	[PA]	Nausea, Headache, fatigue, bradyarrhythmia
VOSEVI	sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/ 100 mg) PO daily	5	[PA]	5	[PA]	headache, fatigue, diarrhea, nausea
ImmunostimulantsPegylated Interferon						
PEGASYS INJ	180mcg SQ once weekly	5		5	[PA]	Fatigue/asthenia, pyrexia, myalgia Boxed warning: may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders

Brand-name drugs are capitalized and generic drugs are listed in the lower-case italics.

[PA] = Prior Authorization



Drug Reference:

1. Online Lexicomp (09/2024): 1100 Terex Road, Hudson, OH 44236
2. Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. Dec 2023. <http://www.hcvguidelines.org/> (Accessed on September 16, 2024)
3. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C | © 2014-2024 AASLD and IDSA